Sugentech Inc.
Financials
Valuation Metrics
Sugentech Inc.'s Market Cap is ₩773B. At end of 2025 it was ₩1028B. Ranked #1452 of 2,421 in KR market (top 60%), #836 of 1,640 on KOSDAQ (top 51%), #55 of 96 in Health Care Equipment & Services (top 57%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 77.27B KRW | KR#1,452/2,421 Sec#55/96 |
| Revenue | 9.78B KRW | KR#2,292/2,421 Sec#82/96 |
| Net Income | -23.15B KRW | KR—/2,421 Sec—/96 |
| Total Assets | 87.28B KRW | KR#1,886/2,421 Sec#58/96 |
| Net Assets | 68.56B KRW | KR#1,697/2,421 Sec#52/96 |
| Employees | 152 | KR#1,321/2,421 Sec#44/96 |
| Value | ||
| P/B | 1.13x | KR#1,567/2,421 Sec#48/96 |
| P/S | 7.90x | KR#2,238/2,421 Sec#81/96 |
| Profitability | ||
| ROE | -33.77% | KR#2,213/2,421 Sec#80/96 |
| ROA | -26.53% | KR#2,291/2,421 Sec#86/96 |
| Op. Margin | -192.84% | KR#2,333/2,421 Sec#87/96 |
| Revenue Growth | -15.96% | KR#2,063/2,421 Sec#87/96 |
| Financial Health | ||
| Debt Ratio | 27.30% | KR#533/2,421 Sec#29/96 |
| Total Debt | 11.50B KRW | KR#1,574/2,421 Sec#49/96 |
| Cash | 9.96B KRW | KR#1,702/2,421 Sec#56/96 |
| Current Ratio | 9.11x | KR#119/2,421 Sec#12/96 |
| Performance | ||
| 1Y Return | -34.17% | KR#1,686/2,421 Sec#48/96 |
| 1M Return | 19.56% | KR#254/2,421 Sec#7/96 |
| From 52W High | -44.06% | KR#1,114/2,421 Sec#35/96 |
| 1Y MDD | -52.99% | KR#1,120/2,421 Sec#38/96 |
| Trading | ||
| Volume | 107,924 shares | KR#748/2,421 Sec#26/96 |
| Trading Value | 500.6M KRW | KR#920/2,421 Sec#27/96 |
| Foreign Own. | 2.26% | KR#1,541/2,421 Sec#56/96 |
| Per Share | ||
| EPS | -1,383 KRW | KR—/2,421 Sec—/96 |
| BPS | 4,095 KRW | KR#1,646/2,421 Sec#42/96 |
Company Info
Established in 2011, the company achieved KONEX listing in 2016 and KOSDAQ transfer listing in 2019, with its main business being the research and development, manufacturing, and sales of in vitro diagnostic medical devices. It commercializes multiple immunoassay blots based on BIO/NANO/IT/A.I fusion technology and offers TRF and fluorescence-based quantitative analysis products for point-of-care diagnostics. In digital healthcare, Sugentech launched the nation's sole digital device for female hormone diagnosis, expanding into the health & beauty category to evolve into a comprehensive wellness platform. Sugentech is headquartered in Yuseong-gu, Daejeon Metropolitan City.